Skip to main content
Livermore
Livermore
ZHEN

Amylyx Pharmaceuticals, Inc.

AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001658551

In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Amylyx Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of AMLX: Q3 2024 compared with Q4 2024
MeasureQ3 2024Of which not filed for Q4 2024Q4 2024Change
Holders1101122+13
Shares43.5M325.0K49.8M+6.68M (+15.5%)
Value$140.8M$1.05M$188.3M+$48.6M (+34.8%)

1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (33)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to AMLX in Q4 2024
InstitutionSharesValue% of portfolio
Boxer Capital Management, LLC1,750,000$6.62M0.56%
Saturn V Capital Management LLC889,073$3.36M1.32%
OrbiMed Advisors LLC348,000$1.32M0.03%
Wellington Management Group LLP209,708$792.7K0.00%
Kennondale Capital Management LLC134,445$508.2K0.55%
ExodusPoint Capital Management, LP106,237$402.0K0.00%
Jump Financial, LLC104,342$394.4K0.01%
Omers Administration Corp66,000$249.5K0.00%
Alps Advisors Inc55,430$209.5K0.00%
Dimensional Fund Advisors LP54,114$204.6K0.00%
Ameriprise Financial Inc50,428$190.6K0.00%
Landscape Capital Management, L.L.C.49,661$187.7K0.02%
Centiva Capital, LP33,831$127.9K0.00%
Tudor Investment Corp Et Al33,687$127.3K0.00%
Wedbush Securities Inc19,914$75.0K0.00%
Engineers Gate Manager LP17,637$66.7K0.00%
Y-Intercept (Hong Kong) Ltd14,809$56.0K0.00%
EntryPoint Capital, LLC13,909$52.6K0.02%
Rpo LLC12,136$45.9K0.06%
Alpine Global Management, LLC12,017$45.4K0.01%
Fox Run Management, L.L.C.11,788$44.6K0.01%
Gsa Capital Partners LLP10,639$40.0K0.00%
R Squared Ltd6,370$24.1K0.02%
Point72 (DIFC) Ltd4,796$18.1K0.00%
US Bancorp4,000$15.1K0.00%
Walleye Trading LLC2,649$10.0K0.00%
GF Fund Management Co. Ltd.1,439$5.44K0.00%
BNP Paribas Arbitrage, SA1,149$4.34K0.00%
Global Retirement Partners, LLC400$1.51K0.00%
Harbour Investments, Inc.90$3400.00%
Catherine Avery Investment Management LLC87$3290.00%
EverSource Wealth Advisors, LLC25$950.00%
SBI Securities Co., Ltd.1$40.00%

Sold out (20)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of AMLX in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Farallon Capital Management, L.L.C.1,150,221$3.73M
First Trust Advisors LP221,626$718.1K
ADAR1 Capital Management, LLC220,906$715.7K
Panagora Asset Management Inc188,465$610.6K
Shay Capital LLC117,328$380.1K
Algert Global LLC106,219$344.1K
HRT Financial LP81,291$263.0K
Graham Capital Management, L.P.67,956$220.2K
Savant Capital, LLC57,565$186.5K
Legacy Advisors, LLC50,000$162.0K
Bank of New York Mellon Corp23,679$76.7K
Premier Path Wealth Partners, LLC20,265$65.7K
Aries Wealth Management15,000$48.6K
Corton Capital Inc.13,104$42.5K
Bayesian Capital Management, LP10,700$34.7K
Atria Wealth Solutions, Inc.10,000$32.4K
Catalyst Funds Management Pty Ltd7,500$24.3K
nVerses Capital, LLC2,100$6.80K
Ronald Blue Trust, Inc.2,104$4.00K
Point72 Asset Management, L.P.200$648

Not filed for Q4 2024 yet (1)

Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AMLX in Q3 2024 that haven't filed for Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Ghost Tree Capital, LLC325,000$1.05M